Sunbather

Importance of the Topic

Efficient and reproducible production of lipid nanoparticles (LNPs) is critical for modern drug delivery platforms, including mRNA vaccines and gene therapies. Robust mixing strategies and seamless transfer to Good Manufacturing Practice (GMP) environments are essential to maintain formulation performance, ensure regulatory compliance, and accelerate clinical development.

Study Objectives and Overview

This application note introduces the Sunbather instrument, part of the Sunny Suite family, designed to streamline the transition of optimized LNP formulations into GMP manufacturing. It highlights how Sunbather reuses established mixing protocols, minimizes equipment changes, and integrates documentation to reduce re-validation efforts.

Applied Methodology

Sunbather employs microfluidic mixing modules (“Sunnies”) in continuous flow, combining an aqueous channel (payload) and an organic channel (lipids) via three mixer geometries:

• Sunny T: classic T-junction mixing for straightforward applications
• Sunny X: cross-junction mixing for enhanced fluid contact area
• Sunny Trident: reverse-angle mixing with integrated in-line dilution to support a wide range of flow rates and ratios

Flow rate ratios from 1:1 to 10:1 and total flow rates from 0.1 to 30 mL/min (per configuration) enable precise control over particle size and encapsulation efficiency.

Used Instrumentation

The Sunbather system comprises:

• Sunbather main unit with replaceable, sterile flow paths
• GMP-ready Sunnies in various channel sizes
• Windows 11 touchscreen PC running 21 CFR Part 11-compliant software
• Peristaltic or piston pumps for accurate fluid delivery
• IQ/OQ documentation, traceable materials data, and extractables profiles

Main Results and Discussion

Sunbather achieves up to 1.8 L/h production while preserving the mixing kinetics and formulation attributes previously established on R&D-scale Sunny instruments. Comparative data show consistent particle diameters (40–200 nm), low polydispersity indices (<0.2), and high encapsulation efficiencies (>90%) across screening, optimization, and GMP scales.

Benefits and Practical Applications

The integrated design reduces process transfer time and validation burden by reusing proven mixing parameters and documentation. Fully replaceable flow paths and compliant software enhance traceability and operator control, making the platform suitable for academic, contract development, and industrial settings.

Future Trends and Potential Applications

Emerging needs in continuous manufacturing, real-time monitoring (PAT), and digital process modeling align with Sunbather’s modular architecture. Future expansions may include inline analytics for dynamic feedback, larger production modules for multi-liter throughput, and integration with automated formulation screening workflows.

Conclusion

Sunbather bridges the gap between laboratory-scale formulation development and GMP production by leveraging consistent mixing technologies, streamlined validation packages, and compliant software. This approach accelerates LNP manufacturing, ensuring reliable, scalable production of advanced therapeutic nanoparticles.

Reference

Unchained Labs. Sunbather Application Note. Rev A, 2024.